# Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

> **NCT01210560** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease

## Interventions

- **DRUG:** Tolvaptan MR
- **DRUG:** Tolvaptan MR
- **DRUG:** Tolvaptan MR
- **DRUG:** Tolvaptan IR
- **DRUG:** Tolvaptan MR

## Key facts

- **NCT ID:** NCT01210560
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01210560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01210560, "Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01210560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*